BRIEF published on 12/17/2025 at 07:35, 20 hours 25 minutes ago Sanofi publie son aide-mémoire pour le quatrième trimestre 2025 Sanofi Modélisation Financière Aide Mémoire 4e Trimestre 2025 Tourné Vers L'avenir
BRIEF published on 12/17/2025 at 07:35, 20 hours 25 minutes ago Sanofi Releases Q4 2025 Aide Mémoire Sanofi Financial Modeling Aide Mémoire Q4 2025 Forward-Looking
BRIEF published on 12/17/2025 at 07:35, 20 hours 25 minutes ago Sanofi publishes the document "Q4 2025 Quick Reference Guide" Financial Results Investors Sanofi Q4 2025 Modeling
BRIEF published on 12/17/2025 at 07:35, 20 hours 25 minutes ago Sanofi publie le document « Q4 2025 Aide mémoire » Résultats Financiers Investisseurs Sanofi Modélisation Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 20 hours 30 minutes ago Press release: Availability of the Q4 2025 Aide memoire Sanofi announces availability of Q4 2025 Aide memoire on the company's website for financial modeling purposes. Q4 2025 results to be published on January 29, 2026 Sanofi Results Aide Mémoire Financial Modelling Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 20 hours 30 minutes ago Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Sanofi annonce la mise en ligne du document 'Q4 2025 Aide mémoire' pour assister la communauté financière dans la modélisation des résultats trimestriels Communication Financière Résultats Trimestriels Sanofi Document Q4 2025
BRIEF published on 12/15/2025 at 07:10, 2 days 20 hours ago Sanofi : résultats de l'étude PERSEUS sur le tolébrutinib décevants Sclérose En Plaques Sanofi Tolebrutinib Étude PERSEUS Résultats D'étude
BRIEF published on 12/15/2025 at 07:10, 2 days 20 hours ago Sanofi Halts Pursuit of Regulatory Registration for Tolebrutinib in PPMS Multiple Sclerosis Tolebrutinib PPMS Trial PERSEUS Study Sanofi R&D
BRIEF published on 12/15/2025 at 07:10, 2 days 20 hours ago Sanofi renonce à l'autorisation de mise sur le marché du tolebrutinib dans le traitement de la SEP progressive primaire Sclérose En Plaques Tolebrutinib Essai PPMS Étude PERSEUS Recherche Et Développement Chez Sanofi
BRIEF published on 12/15/2025 at 07:10, 2 days 20 hours ago Sanofi: PERSEUS study results on tolebrutinib disappointing Study Results Multiple Sclerosis Sanofi Tolebrutinib PERSEUS Study
Published on 12/18/2025 at 00:55, 3 hours 5 minutes ago Molten Metals Corp. Announces Flow-Through Financing
Published on 12/18/2025 at 00:00, 4 hours ago Right Season Investments Announces Name Change to FutureGen Industries Corp.
Published on 12/17/2025 at 23:15, 4 hours 45 minutes ago Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 13 hours ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/18/2025 at 01:10, 2 hours 50 minutes ago Samsung To Unveil New AI-Connected Living Lineup at CES 2026
Published on 12/18/2025 at 00:50, 3 hours 10 minutes ago Historic production of graphene enhanced cement successfully completed
Published on 12/17/2025 at 22:05, 5 hours 55 minutes ago Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques
Published on 12/17/2025 at 22:05, 5 hours 55 minutes ago Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Published on 12/17/2025 at 21:22, 6 hours 38 minutes ago EQS-Adhoc: DATAGROUP SE: DATAGROUP SE Management Board plans dividend of EUR 0.04 per share
Published on 12/17/2025 at 20:39, 7 hours 21 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 7 hours 21 minutes ago Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 8 hours 30 minutes ago Evolution de la composition du Conseil d’Administration
Published on 12/17/2025 at 18:00, 10 hours ago Outstanding Shares and Voting Rights Statement at 30 November 2025
